Thus, our findings about the elevated granzyme B levels (along with activation of FASL) in a similar experimental setup suggest a yet unknown mechanism that may be of interest for future NSCLC immunotherapy. This evidence concerns the gene FASLG and non-small cell lung carcinoma.